In dogs with heart disease, mitochondrial fatty acid oxidation, glycolysis and ketone body utilization are disrupted (Freeman et al., 2023; Li et al., 2021) opening the possibility of benefit from SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is heart disorder.